Cue Biopharma, Inc. (CUE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on July 10, 2026, covering events occurring on July 9, 2026. The Company, a biopharmaceutical firm based in Boston, Massachusetts, is an emerging growth company focused on clinical development. The filing primarily addresses a material definitive agreement for a private placement of equity securities and significant executive compensation grants.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company agreed to raise gross proceeds of approximately $50.0 million through a private placement.
- Securities Issued:
- 1,418,071 shares of Common Stock at $33.21 per share.
- Pre-funded warrants to purchase up to 87,500 shares of Common Stock at $33.209 per warrant.
- Investors: Includes accredited investors such as Cormorant Asset Management and Columbia Threadneedle Investments.
- Use of Proceeds: Net proceeds are intended to fund clinical development and general corporate purposes.
- Financial Position: The filing notes the Company has a history of losses, limited cash, and a current "going concern" determination indicating insufficient capital to continue operations beyond the next twelve months without additional financing.
Material Changes and Corporate Actions
- Private Placement: Entered into a Securities Purchase Agreement for the issuance of Common Stock and Pre-Funded Warrants. Closing is expected on July 13, 2026.
- Registration Rights: Executed a Registration Rights Agreement requiring the filing of a registration statement for the resale of securities within 30 days of closing.
- Executive Compensation: Granted an aggregate of 1,064,492 Restricted Stock Units (RSUs) to employees and executive officers under the 2026 Stock Incentive Plan.
- Shao-Lee Lin (CEO): 655,074 RSUs.
- Sumita Ray (Chief Legal and Compliance Officer): 109,178 RSUs.
- Michael Meluzio (Principal Accounting Officer): 81,884 RSUs.
- Non-employee directors: 21,800 RSUs each.
Outlook, Risks, and Contingencies
Management intends to use the proceeds to remediate the "going concern" determination and fund ongoing clinical trials. The filing includes a cautionary note regarding forward-looking statements and highlights several material risks:
- Going Concern: The Company faces uncertainty regarding its ability to obtain adequate financing to fund operations in the near term.
- Development Risks: Potential setbacks in research and development, including negative clinical trial results or inability to replicate preclinical data.
- Regulatory Risks: Dependence on FDA approvals and potential delays in regulatory submissions.
- Collaboration Risks: Reliance on maintaining license agreements with Ascendant Health Sciences, Ltd. and collaborations with ImmunoScape Pte. Ltd.
- Closing Conditions: The private placement is subject to customary closing conditions.
Investor Verification Checklist
- Verify the closing of the $50.0 million private placement on or around July 13, 2026.
- Confirm the filing and effectiveness of the registration statement for the resale of the new securities within the 30-day deadline.
- Review the Company's most recent 10-K or 10-Q to assess the current cash runway and the specific impact of this financing on the "going concern" qualification.
- Monitor the status of the License Agreement with Ascendant Health Sciences, Ltd. and the collaboration with ImmunoScape Pte. Ltd.
- Track the vesting schedule and performance conditions attached to the 1,064,492 RSUs granted to executives.